Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of AstraZeneca's Saruparib?
Saruparib is a small molecule commercialized by AstraZeneca, with a leading Phase III program in Metastatic Prostate Cancer. According to...
Saruparib by AstraZeneca for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Saruparib is under clinical development by AstraZeneca and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Negative...
Saruparib by AstraZeneca for Metastatic Prostate Cancer: Likelihood of Approval
Saruparib is under clinical development by AstraZeneca and currently in Phase III for Metastatic Prostate Cancer. According to GlobalData, Phase...
Saruparib by AstraZeneca for Hormone-Sensitive Prostate Cancer: Likelihood of Approval
Saruparib is under clinical development by AstraZeneca and currently in Phase II for Hormone-Sensitive Prostate Cancer. According to GlobalData, Phase...
Saruparib by AstraZeneca for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Saruparib is under clinical development by AstraZeneca and currently in Phase III for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...